ALPN News and Press, Alpine Immune Sciences Inc. From 03/07/24

2024-03-07 15:30:54 ET Summary Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate. Povetacicept has shown promising results in a Phase 2 study for the tr...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.37% on the day to $35.05. Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherap...

2024-02-28 22:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-18 05:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-15 15:11:25 ET More on Alpine Immune Sciences Alpine Immune Looks Highly Interesting Except For The Price (Rating Upgrade) Alpine amends acazicolcept deal with AbbVie, ends Phase 2 study early Seeking Alpha’s Quant Rating on Alpine Immune Sciences ...

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

2024-01-29 16:59:37 ET Gainers: Sanmina Corporation ( SANM ) +15% . Woodward ( WWD ) +7% . F5  ( FFIV ) +7% . Super Micro Computer ( SMCI ) +6% . Alpine Immune Sciences ( ALPN ) +4% . Losers: J-Long Group  ( J...

2024-01-27 15:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-25 15:30:27 ET Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and ...

2023-12-21 17:21:38 ET Alpine Immune Sciences ( NASDAQ: ALPN ) said it has amended its 2020 option and license agreement with AbbVie ( ABBV ) for acazicolcept and will be stopping a Phase 2 study for the drug early to allow for early assessment of the data. Alpine said enrol...